Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
  • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D257/04—Five-membered rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases
• the invention relates to nitrate derivatives of cilostazol useful in the treatment of vascular and metabolic diseases.
• vascular and metabolic diseases are, despite cancer, the leading causes of death in the western world. Although many different ways of treating vascular and metabolic diseases are known, there is still a need for improved medication. Life-style modifications and drug therapy can decrease and delay the morbidity and mortality associated with these diseases. Treatments which have been proven to reduce the risk for morbidity and mortality in vascular diseases have been typically shown to either improve impaired vascular function or to delay/prevent the progression of vascular dysfunction caused by hypertension, atherosclerosis or other classical metabolic risk factors. Examples for such treatments are calcium channel blockers, beta blockers, angiotension-enzyme converting inhibitors or angiotension receptor blockers.
• nitrates specifically nitrate esters, such as glyceryl trinitrate (nitroglycerine), isosorbide dinitrate, or penta- erythrityl tetranitrate, which act all as coronary vasodilators and improve symptoms and exercise tolerance.
• organic nitrates e.g. mononitrates and trinitrates
• cilostazol a phospho- diesterase III inhibitor
• pentoxifylline a phospho- diesterase III inhibitor
• Cilostazol U.S. Patent 4,277,479 acts as a direct arterial vasodilator.
• cilostazol has been proposed to have beneficial effects on plasma lipoproteins, increasing plasma high density lipoprotein cholesterol and apolipoproteins.
• Nitrate esters of drugs in general are described in WO 00/61357.
• Diazeniumdiolate derivatives have recently been recognized as alternatives for nitrates, setting free two molecules of NO under physiological conditions.
• a diazeniumdiolate derivative of tacrine is described by L. Fang et al., J. Med. Chem. 51 , 7666-7669 (2008).
• the invention relates to compounds of formula
• R 2 and R 3 are both ethyl or 2-aminoethyl, or NR 2 R 3 together represent pyrrolidine, piperidine, piperazine or 4-methylpiperazine.
• the invention relates to pharmaceutical compositions comprising the compounds as defined hereinbefore, to the compounds as defined hereinbefore for the treatment of vascular and metabolic diseases, and to a method of treatment of vascular and metabolic diseases using the compounds and pharmaceutical compositions as defined hereinbefore.
• the compounds of the invention represent useful medicaments for the treatment of vascular and metabolic diseases, for example, atherosclerosis, in particular connected with hypertension, also ocular and pulmonary hypertension, heart failure, in particular chronic heart failure after a heart attack (myocardial infarction), stroke, angina pectoris, cerebrovascular disease, coronary artery disease, left ventricular dysfunction and hypertrophy, and peripheral arterial disease (PAD), in particular intermittent claudication.
• vascular and metabolic diseases for example, atherosclerosis, in particular connected with hypertension, also ocular and pulmonary hypertension, heart failure, in particular chronic heart failure after a heart attack (myocardial infarction), stroke, angina pectoris, cerebrovascular disease, coronary artery disease, left ventricular dysfunction and hypertrophy, and peripheral arterial disease (PAD), in particular intermittent claudication.
• the compound of formula 1 wherein A is hydrogen, is known under the name cilostazol.
• the compound of formula 1 A, wherein A is hydrogen is a tautomeric form of cilostazol, wherein the amide function is present as an oxy-imine function (keto-enol tautomerisim).
• the oxy-imine function cannot revert to the amide function and form a tautomeric equilibrium.
• Such a compound of formula 1 A represents a stable regio-isomer of the corresponding compound of formula 1.
• Ci- 4 -alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, preferably methyl, ethyl or n-propyl, in particular methyl.
• Vascular diseases considered are, for example, hypertension and atherosclerosis and typical related consecutive diseases and their corresponding complications, in particular, ocular and pulmonary hypertension, chronic heart failure, heart failure after a heart attack (myocardial infarction), cerebral ischaemia in general and, specifically, transient ischaemic attacks (TIAs), prolonged neurological deficits (PRIND), stroke (ischaemic and non- ischaemic), chronic cerebrovascular diseases, stable and unstable angina pectoris, coronary artery disease, cardiac dysfunction, specifically left or right ventricular dysfunction and hypertrophy, peripheral arterial disease (PAD) at all stages, specifically including abnormalities in micro- and macrovascular function such as neuropathy, endothelial dysfunction, cold feet, impaired wound healing, ischaemic ulcers and necrosis, critical limb ischaemia, intermittent claudication, chronic or intermittent pain syndromes related to peripheral artery disease, polyneuropathy, and chronic and acute inflammatory vascular diseases.
• TIAs transient ischaemic attacks
• PRIND prolonged neurological deficits
• treatment and prophylaxis is considered of complications after peripheral vascular interventions such as balloon angioplasty and/or stenting, portal hypertension, chronic inflammatory vascular diseases, mixed connective tissue diseases with vascular complications, treatment of vascular complications in patients with Morbus Raynaud or Morbus Osier, treatment of typical micro- and macro-vascular complications of diabetes mellitus, abnormalities of platelet function such as increased platelet adhesion and resulting hypercoagulability, and conditions typically accompanying vascular diseases as described above.
• peripheral vascular interventions such as balloon angioplasty and/or stenting, portal hypertension, chronic inflammatory vascular diseases, mixed connective tissue diseases with vascular complications, treatment of vascular complications in patients with Morbus Raynaud or Morbus Osier, treatment of typical micro- and macro-vascular complications of diabetes mellitus, abnormalities of platelet function such as increased platelet adhesion and resulting hypercoagulability, and conditions typically accompanying vascular diseases as described above.
• Metabolic diseases considered are, for example, diabetes mellitus type 1 and 2, impaired glucose tolerance, all dyslipidaemias such hypercholesterolemia, hypertriglyceridaemia, abnormalities of high density lipoproteins alone or in combinations with other dyslipidaemias, abnormalities of Apolipoprotein A1 or other subfractions of lipoproteins, and other metabolic diseases resulting in vascular complications and/or impaired platelet function.
• Compounds of formula 1 and 1 A can be manufactured by methods well known in the art.
• cilostazol i.e. the compound of formula 1 , wherein A is hydrogen
• an acylating compound or an alkylating compound respectively, further carrying one or two bromine, chlorine or iodine atoms, according to standard procedures well known in the art.
• the bromine, chlorine or iodine is replaced by a nitrate ester or a diazeniumdiolate function by reaction with silver nitrate, or with a diazeniumdiolate in the presence of strong base in a dipolar aprotic solvent, respectively.
• the acylating or alkylating compound carries one or two hydroxy functions or protected hydroxy functions. These hydroxy groups are then transformed to a nitrate ester with nitric acid.
• a third synthesis procedure involves alkylation or acylation with the corresponding preformed reactive nitroxyalkyl or nitroxyacyl derivative, e.g. the 4-nitroxybutanoic acid pentafluorophenol ester.
• R 2 and R 3 are both ethyl, or NR 2 R 3 together represent pyrrolidine.
• compositions that comprise a compound of formula 1 or 1 A as active ingredient and that can be used especially in the treatment of the diseases mentioned above.
• Compositions for enteral administration such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, to warm-blooded animals, especially humans, are especially preferred.
• the compositions comprise the active ingredient alone or, preferably, together with a pharmaceutically acceptable carrier.
• the dosage of the active ingredient depends upon the disease to be treated and upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, and the mode of administration.
• the present invention relates especially to pharmaceutical compositions that comprise a compound of formula 1 or 1 A, and at least one pharmaceutically acceptable carrier.
• the invention relates also to pharmaceutical compositions for use in a method for the prophylactic or especially therapeutic management of the human or animal body, in particular in a method of treating a vascular and metabolic disease, especially those mentioned above.
• the invention relates also to processes and to the use of compounds of formula 1 or 1 A for the preparation of pharmaceutical preparations which comprise compounds of formula 1 or 1 A as active component (active ingredient).
• a pharmaceutical composition for the prophylactic or especially therapeutic management of a vascular and metabolic disease, of a warm-blooded animal, especially a human, comprising a novel compound of formula 1 or 1 A as active ingredient in a quantity that is prophylactically or especially therapeutically active against the said diseases, is likewise preferred.
• the pharmaceutical compositions comprise from approximately 1% to approximately 95% active ingredient, single-dose administration forms comprising in the preferred embodiment from approximately 20% to approximately 90% active ingredient and forms that are not of single-dose type comprising in the preferred embodiment from approximately 5% to approximately 20% active ingredient.
• Unit dose forms are, for example, coated and uncoated tablets, ampoules, vials, suppositories, or capsules.
• Further dosage forms are, for example, ointments, creams, pastes, foams, tinctures, lipsticks, drops, sprays, dispersions, etc.
• Examples are capsules containing from about 0.001 g to about 1 .0 g active ingredient.
• compositions of the present invention are prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving or lyophilizing processes.
• compositions of the active ingredient Preference is given to the use of solutions of the active ingredient, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example in the case of lyophilized compositions comprising the active ingredient alone or together with a carrier, for example mannitol, can be made up before use.
• the pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes.
• the said solutions or suspensions may comprise viscosity-increasing agents, typically sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, or gelatins, or also solubilizers, e.g. Tween 80® (polyoxyethylene(20)sorbitan mono-oleate).
• viscosity-increasing agents typically sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, or gelatins, or also solubilizers, e.g. Tween 80® (polyoxyethylene(20)sorbitan mono-oleate).
• Suspensions in oil comprise as the oil component the vegetable, synthetic, or semisynthetic oils customary for injection purposes.
• liquid fatty acid esters that contain as the acid component a long -chained fatty acid having from 8 to 22, especially from 12 to 22, carbon atoms.
• the alcohol component of these fatty acid esters has a maximum of 6 carbon atoms and is a monovalent or polyvalent, for example a mono-, di- or trivalent, alcohol, especially glycol and glycerol.
• vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and groundnut oil are especially useful.
• the manufacture of injectable preparations is usually carried out under sterile conditions, as is the filling, for example, into ampoules or vials, and the sealing of the containers.
• Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations, and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starches, for example corn, wheat, rice or potato starch, methylcellulose, hydroxypropyl methyl- cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, crosslinked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate.
• Additional excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.
• Tablet cores can be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropyl - methylcellulose phthalate. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient.
• concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide
• suitable organic solvents or solvent mixtures or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropyl - methylcellulose phthalate.
• Dyes or pigments may be added to the tablets or tablet coating
• compositions for oral administration also include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer, such as glycerol or sorbitol.
• the hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, such as corn starch, binders, and/or glidants, such as talc or magnesium stearate, and optionally stabilizers.
• the active ingredient is preferably dissolved or suspended in suitable liquid excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example of the polyoxy- ethylene sorbitan fatty acid ester type, may also be added.
• suitable liquid excipients such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example of the polyoxy- ethylene sorbitan fatty acid ester type, may also be added.
• compositions suitable for rectal administration are, for example, suppositories that consist of a combination of the active ingredient and a suppository base.
• Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols.
• aqueous solutions of an active ingredient in water-soluble form for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers, are especially suitable.
• the active ingredient optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents.
• Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions.
• Preferred preservatives are, for example, antioxidants, such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid.
• the present invention relates furthermore to a method for the treatment of a vascular and metabolic disease, which comprises administering a compound of formula 1 or 1 A, wherein the radicals and symbols have the meanings as defined above for formula 1 and 1 A, in a quantity effective against said disease, to a warm-blooded animal requiring such treatment.
• the compounds of formula 1 or 1 A can be administered as such or especially in the form of pharmaceutical compositions, prophylactically or therapeutically, preferably in an amount effective against the said diseases, to a warm-blooded animal, for example a human, requiring such treatment.
• the daily dose administered is from approximately 0.001 g to approximately 5 g, preferably from approximately 0.25 g to approximately 1.5 g, of a compound of the present invention.
• the present invention relates especially also to the use of a compound of formula 1 or 1 A, as such or in the form of a pharmaceutical formulation with at least one pharmaceutically acceptable carrier for the therapeutic and also prophylactic management of a vascular and metabolic disease, in particular of peripheral arterial disease.
• the invention provides a method for the treatment of a metabolic disease, which comprises administering a compound of formula 1 or 1 A, wherein the radicals and symbols have the meanings as defined above, in a quantity effective against said disease, to a warm-blooded animal requiring such treatment.
• Example 1 2-
• the compound is prepared from the corresponding diol 3 (Example 2) in the following way: 1 -[4-Hydroxy-3-(hydroxymethyl)butanoyl]-6-[4-(1 -cyclohexyl-1 H-tetrazol-5- yl)butoxy]-3,4-dihydroquinolin-2(1 H)-one (23.7 g, 0.049 mol) is added slowly to 15 g HNO 3 (100%, 0.24 mol) at -10 ⁇ €. The resulting mixture is stirred for 10 min at O 0 C, 15 g ice added to it, and stirring continued for 2 h at room temperature until brown gases (NO x ) disappear.
• 1 -[4-Hydroxy-3-(hydroxymethyl)butanoyl]-6-[4-(1 -cyclohexyl-1 H-tetrazol-5- yl)butoxy]-3,4-dihydroquinolin-2(1 H)-one (23.7 g
• the mixture is cooled to ⁇ 'O, and 2-butanol added carefully.
• the organic phase is dried with MgSO 4 .
• the resulting crude mixture is purified as above to give the desired dinitrate.
• reaction mixture is diluted with 1000 ml_ CH 2 CI 2 , and washed with 1 N HCI, saturated NaHCO 3 solution and brine.
• the organic phase is dried over sodium sulphate, and concentrated.
• the residue is purified by flash chromatography (silica gel, CH 2 CI 2 /tert-butyl methyl ether 90:10) to give the title compound in 42% yield.
• Example 6 1 -(4-Nitroxybutanoyl)-6-[4-(1 -cyclohexyl-1 /-/-tetrazol-5-yl)butoxy1-3,4- dihydroquinolin-2(1 H)-one (7)
• Example 7 1 -
• Example 8 1 -(2-Nitroxyethylaminocarbonyloxymethyl)-6-[4-(1 -cyclohexyl-1 H-tetrazol-5- yl)butoxy1-3,4-dihydroquinolin-2(1 /-/)-one (9) and 1 -[ ⁇ /-(2-nitroxyethyl)- ⁇ /-(2-nitroxyethyl- aminocarbonyloxymethyl)-aminocarbonyloxymethyl1-6-[4-(1 -cvclohexyl-1 /-/-tetrazol-5- yl)butoxy1-3,4-dihydroquinolin-2(1 H)-one (10)

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=40456966

Family Applications (1)

Country Status (14)

Families Citing this family (20)

Citations (2)

Family Cites Families (5)

• 2008
  • 2008-12-02 EP EP08170435A patent/EP2194048A1/en not_active Withdrawn
• 2009
  • 2009-12-01 EP EP09793498A patent/EP2367803A1/en not_active Withdrawn
  • 2009-12-01 CA CA2745252A patent/CA2745252A1/en not_active Abandoned
  • 2009-12-01 MX MX2011005744A patent/MX2011005744A/es not_active Application Discontinuation
  • 2009-12-01 US US13/131,722 patent/US8426597B2/en not_active Expired - Fee Related
  • 2009-12-01 RU RU2011126607/04A patent/RU2011126607A/ru unknown
  • 2009-12-01 SG SG2011038213A patent/SG171423A1/en unknown
  • 2009-12-01 BR BRPI0923300A patent/BRPI0923300A2/pt not_active Application Discontinuation
  • 2009-12-01 AU AU2009324123A patent/AU2009324123A1/en not_active Abandoned
  • 2009-12-01 KR KR1020117015258A patent/KR20110088598A/ko not_active Application Discontinuation
  • 2009-12-01 JP JP2011538999A patent/JP2012510502A/ja not_active Ceased
  • 2009-12-01 CN CN200980149072XA patent/CN102245583A/zh active Pending
  • 2009-12-01 WO PCT/EP2009/066159 patent/WO2010063724A1/en active Application Filing
• 2011
  • 2011-05-30 IL IL213214A patent/IL213214A0/en unknown
  • 2011-05-31 ZA ZA2011/04011A patent/ZA201104011B/en unknown

Patent Citations (2)

Also Published As

Similar Documents

Legal Events